Dr. Ajai Arvind Dandekar, MD

Dr. Dandekar practices at UW Medical Center - Montlake in Seattle, Washington, part of University of Washington.

Dr. Dandekar's NPI, 1669587366, was assigned on August 20, 2006. Dr. Dandekar graduated from University of Iowa, RJ & L Carver College of Medicine in 2005. Dr. Dandekar holds Washington license MD00048449.

Dr. Dandekar's primary practice is UW Medical Center - Montlake, at 1959 NE Pacific St Box 356151, Seattle, WA 98195 in King County. The practice phone is (206) 598-3300.

Dr. Dandekar's primary practice is UW Medical Center - Montlake in Seattle, Washington, part of University of Washington. The medical group on file is UW Physicians. Dmand AI also links Dr. Dandekar to 1 more hospital and 1 hospital outpatient department, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Dandekar practices, 3 sites in all. Vendor and product names are available with a free account.

Pulmonary disease is Dr. Dandekar's primary specialty in the NPI Registry, under taxonomy code 207RP1001X. Dr. Dandekar is licensed in Washington.

CMS data shows 47 Medicare services from Dr. Dandekar across 2 procedure codes in 2024, for 26 Medicare patients. Medicare paid $6,769 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 26 Medicare patients who saw Dr. Dandekar in 2024. The largest group is under 65, with 13 patients. 69% of them have high blood pressure, and 50% have anxiety. 46% are also on Medicaid. Their average risk score is 3.31, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Dandekar's median patient age at 44, with 51% women.

In 2024, Dr. Dandekar wrote 277 Medicare Part D claims for 35 patients. CMS names the drug for 140 of them, across 4 drugs with 11 or more claims each, at $2,780,551 in total drug cost. In 2023, CMS named 169 claims across 6 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 94 out of 100 for Dr. Dandekar for performance year 2024, reported through an alternative payment model (APM). Dr. Dandekar accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Dandekar as offering telehealth.

CMS Open Payments shows 4 general payments to Dr. Dandekar from 2 drug and device companies from 2016 to 2018. Travel and lodging make up the largest share, 72% of the total. Gilead Sciences, Inc. paid the most, $1,067.

Dr. Dandekar graduated from University of Iowa, RJ & L Carver College of Medicine in 2005.